OBI Pharma

OBI Pharma, Inc. is a clinical-stage oncology company that researches and develops novel therapeutic agents for unmet medical needs in cancer. Its pipeline includes Adagloxad simolenin in Phase 3 for triple-negative breast cancer, OBI-833 in Phase 2 for non-small cell lung cancer, OBI-3424 which has completed Phase 2 for liver hepatocellular carcinoma and acute lymphocytic leukemia, OBI-992 in Phase 1 for solid tumors, and OBI-902 and OBI-904 in preclinical stage for solid tumors. OBI-999 is a first-in-class antibody-drug conjugate (ADC) with proprietary linker technology providing a consistent drug-to-antibody ratio (DAR) for cancer treatment, and BsADC is in discovery stage for solid tumors. The company also engages in investing and trading, manufacture and wholesale of western medicines, and biotechnology research and development. Founded in 2002, OBI Pharma is headquartered in Taipei, Taiwan.